Background: Equine herpesvirus-associated myeloencephalopathy is the result of endothelial cell infection of the spinal cord vasculature with equine herpesvirus-1 (EHV-1) during cell-associated viraemia. Endothelial cell infection requires contact between infected peripheral blood mononuclear and endothelial cells. Inflammation generated during viraemia likely upregulates adhesion molecule expression on both cell types increasing contact and facilitating endothelial cell infection. Objectives: Evaluating the role of anti-inflammatory drugs in decreasing endothelial cell infection with EHV-1. Study design: In vitro assay, crossover design, multiple drug testing. Methods: In vitro modified infectious centre assay using immortalised carotid artery endothelial cells or primary brain endothelial cells with plaque counts per well as outcome. Cells were either anti-inflammatory drug treated or left untreated. Results: Significant reduction of plaque count when cells were treated compared with untreated cells. No dose-dependent effect when drug concentrations were increased to 109 dose. Treatment of both peripheral blood mononuclear cells (PBMC) and endothelial cells (EC) is required for significant plaque count reduction. Main limitations: In vitro study. Conclusions: Anti-inflammatory drugs decrease infection of endothelial cells likely by reducing contact between EHV-1 infected PBMC and endothelial cells in vitro. The role of adhesion molecules in this process needs further investigation. In vitro results suggest anti-inflammatory drug therapy during EHV-1 infection and viraemia in horses could be clinically relevant.
Introduction
Equine herpesvirus-associated myeloencephalopathy (EHM) is a serious secondary complication of Equine herpesvirus-1 (EHV-1) infections in horses worldwide. Equine herpesvirus-associated myeloencephalopathy is thought to be the result of a response of the central nervous system (CNS) vasculature to endothelial cell (EC) infection with EHV-1 [1] . Primary infection occurs in the upper respiratory tract and leads to a cell associated viraemia in peripheral blood mononuclear cells (PBMC). Intracellular EHV-1 then reaches the small vessels of the CNS, primarily those of the spinal cord (and the choroidal vasculature of the eye) [2, 3] . Endothelial cell infection results in multi-focal vascular compromise with subsequent secondary ischaemic damage to the CNS parenchyma. A similar pathogenesis is proposed to cause placental separation and fetal infection during EHV-1 abortions [4] . Cell associated viraemia during experimental in vivo infections has been identified in all fractions of PBMC with most frequent occurrence in monocytes, CD8 + and B lymphocytes, while it has been least frequently detected in CD4 + lymphocytes [5] .
Equine herpesvirus-1 enters the host cell through viral envelope glycoprotein interaction with certain host receptors, or through endocytosis [6] . This entry mechanism is thought to be primarily through MHC I and can be reproduced in vitro by adding (free) virus in suspension to receptive cells in culture [7] . However, in previous in vitro experiments, Goehring et al. [8] were able to show that in the concurrent presence of antigen-specific serum neutralising antibody in the media, contact between the virus infected PBMC and EC is essential for EC infection. When contact was disabled, EC infection was prevented. These findings suggest that MHC I is likely the actual cell entry mechanism, while virus has to be brought in close contact with the EC for infection.
MHC I is ubiquitously expressed in tissues including all vascular EC; however, EHV-1 infection of EC during viraemia is unique to endothelia of CNS and vasculature of the (late gestational) uterus [9] . Peripheral blood leucocytes (PBL) interact with EC for immune surveillance, e.g. CD8 + lymphocytes and for cell extravasation [10] . The interaction of EHV-1 infected PBMC with EC is unlikely to be a one-step process, but requires tethering and rolling of PBL over the EC luminal surface, followed by increasingly strong binding and finally interaction with an individual EC or at intercellular junctions. A series of cell adhesion molecules (CAM) on EC and PBL orchestrate this process. Interestingly, expression levels of CAM are different for each vascular bed and while some CAM are constitutively expressed, others are induced by circulating or locally produced inflammatory mediators, or through paracrine effects of neighbouring parenchymal cells. Under physiological conditions the CNS vasculature typically expresses minimal CAM, which is likely a protective mechanism of the blood-brain barrier to maintain its immune privilege [11] . However, CAM are quickly induced by inflammatory mediators. Furthermore, it has been shown that drug families with anti-inflammatory properties are able to interfere with CAM upregulation, inhibiting PBL adhesion and/or extravasation [12, 13] .
Various anti-inflammatory drug classes that differ in their mode of action are being used in horses. A common mode of action is to cause a decrease in inflammatory mediator production and through interference of CAM upregulation slowing down leucocyte extravasation. Assuming that anti-inflammatory drugs have a decreasing effect on CAM expression, we hypothesised that these drugs will decrease the contact frequency of PBMC, some of which are infected with EHV-1, resulting in a decreased EC infection during EHV-1 infection. To test this hypothesis we incubated in vitro EHV-1-infected PBMC and monolayers of EC with selected antiinflammatory drugs in a previously established in vitro assay simulating contact between cells [8] . As EC infection in this assay resulted in visible plaques in the monolayer we compared the plaque counts of drug-treated to untreated control wells in an in vitro carotid artery or CNS-EC culture system.
Materials and methods

Overview of experimental set-up
A series of pre-experiments were conducted to determine the effect of drug treatment on the assay systems. These pre-experiments were followed by three independent experiments designed to determine the effects of drug treatment on EC infection via EHV-1 infected PBMC.
For the main experiments we used an established infectious centre assay (ICA) with modifications in which PBMC from individual horse donors were infected with EHV-1 in vitro and were layered onto a monolayer of EC to allow contact-mediated EC infection. An essential aspect of this assay is that a predetermined titre of EHV-1 virus neutralising antibodies is added to the media to prevent EC infection via an extracellular route after egress from infected PBMC or EC [8] . Experimental conditions between the three experiments differed regarding: 1) Which drugs were used; 2) whether immortalised carotid artery EC (iEC) (experiment 1) or CNS (brain)-derived EC (BEC) were used (Experiments 2 and 3); 3) whether drug treatment (Tx) was applied to cells only prior and during contact time, or during the entire assay time including a 48 h post-contact period (Experiment 2) and 4) whether differences in assay outcome can be detected if only EC or PBMC were treated compared with treating both cell types or none (Experiment 3).
Drugs evaluated
The following anti-inflammatory drugs were evaluated: acetylsalicylic acid . Concentrations used for the in vitro assay were based on published in vivo therapeutic concentrations established for the horse (drug concentration per mL plasma) and achieved after intravenous (i.v.) application of ASP at 20 mg/ kg bwt; a LIDO loading dose of 1.3 mg/kg bwt over 5 min, followed by maintenance constant rate infusion (CRI) of 50 lg/kg bwt/min; FIRO multiple once every 24 h i.v. dosing of 0.1 mg/kg bwt; FLX multiple once every 12 h i.v. dosing of 1.1 mg/kg bwt and DEX single i.v. dose of 0.05 mg/kg bwt. This dosing regimen leads to plasma concentrations that fluctuate between maximal (C max ) and minimal (effective) concentration (C min ) with the exception of a CRI administration, which results in a constant plasma drug concentration (e.g. LIDO). Therefore, concentrations added to media in our in vitro system were chosen at a concentration of 50% between C min and C max were as follows and are referred to as '19' concentrations in the text: ASP (5 lg/mL) [14] , LIDO (1 lg/mL) [15] , FIRO (0.1 lg/mL) [16], FLX (2 lg/mL) [17] and DEX (5 ng/mL) [18] .
Any drug treatment is indicated as 'Tx' in the text, media control as 'NTx'. To evaluate for a dose-dependent effect we also used 109 concentrations of all drugs. As we used commercially available drugs we separately tested the additives or solvents: glycerol formal e (600 mg/mL product [ 
Virus
Equine herpesvirus-1 strain Ohio 03 (OH03) at 10 7 PFU/mL was used for all experiments. The virus was provided to us by Dr N. Osterrieder (FU Berlin, Germany) and originated from an EHM outbreak in Findlay, Ohio, in 2003 [19] . Since then the strain has been used for various in vitro and in vivo studies by several research groups [5, 20] . The virus was propagated on equine dermal cells and aliquoted at a concentration of 10 7 PFU/vial.
Endothelial cell monolayers for ICA
We used monolayers of iEC or BEC for the ICA. Isolation, storage and culture of EC have been described in detail [8] . In summary, aliquots of stored frozen iEC (at passage 3) or primary BEC (aliquots stored frozen from eight horses) were grown to confluency in 48 well plates g in advanced Minimum Essential Media (MEM) h , containing 10% fetal bovine serum i and penicillin/dihydrostreptomycin j (200 iu/mL; 200 mg/mL). Media for BEC culture also contained 5% horse serum i and endothelial cell growth factor k (100 lg/mL). For BEC the first 24 h after seeding in collagen precoated wells were followed by a purification step with puromycin e . [8] . A standard total volume of 250 lL of media was used per well.
Peripheral blood mononuclear cell source and in vitro infection
Eight healthy institution-owned mixed-breed adult horses served as PBMC donors. There had not been a recognised EHV-1 infection in these horses within 5 years prior to the start of the experiments. The pre-experiments were conducted using PBMC aliquots of any of the eight horses (individual donor-derived [idd] PBMC). Peripheral blood mononuclear cells from an individual horse were isolated by ficollhypaque gradient centrifugation, washed and aliquoted at a final cell concentration per aliquot of 2 9 10 6 PBMC/mL. Infection of PBMC with EHV-1 strain OH03 was done at an MOI of 0.1 for 4 h and was followed by adding media containing 5% of previously collected serum of a horse with a known EHV-1 serum neutralising antibody titre of 1:2048. Aliquots of the same serum have been used in this study and in previous experiments. At the time of use, aliquots were in storage at À80°C for about 2 years.
Pre-experimental assays
Prior to Experiments 1-3, drugs or their additives were tested for possible effects on iEC or PBMC metabolism, as well as for potential effects on the virus' ability to infect cells or viral replication efficacy. All experiments described in this section were done in triplicate. First, an AlamarBlue l assay was used to evaluate cellular metabolism of uninfected iEC or PBMC aliquots from eight donors at various drug concentrations. Cells were incubated for 24 h with media alone (NTx) or with serially diluted Tx starting at a 1009 concentration of published therapeutic plasma concentrations. Then, AlamarBlue was added for 6 h. As nonfluorescent resazurin in AlamarBlue is metabolised to fluorescent resorufin during physiological cell metabolism, the absorbance measured at 530 nm in NTx was compared with Tx. To further test whether Tx affects the infection of PBMC with EHV-1, or whether Tx has an influence on virus replication in PBMC, we infected PBMC with virus (see above) and incubated with Tx or NTx simultaneously for additional 10 h. Peripheral blood mononuclear cells were then permeabilised and incubated with FITC conjugated, anti-goat EHV-1 polyclonal antiserum m [8] . Using flow cytometry n , the percentage fluorescent cells in each group was reported and compared. Furthermore, aliquots of infected Tx or NTx PBMC were analysed by quantitative PCR as previously described, reporting the genomic copy numbers of EHV-1 glycoprotein B (gB) [21] . As the drugs LIDO, FIRO or DEX were used exclusively in Experiments 2 and 3, we tested whether individual drug treatment of BEC monolayers had an effect on EHV-1 BEC-infection when applying a drug-treated (cell free) virus suspension at two different titres (1 9 10 2 or 1 9 10 3 PFU/mL) to the monolayer. These titres corresponded to a MOI of 0.0001 and 0.001, respectively, as there were approximately 1 9 10 6 cells/well.
Main experiments 1-3
All set-ups of Experiments 1-3, in particular drug incubation times, are summarised in Table 1 . All experiments comprise the result of series of ICAs. In a single ICA only iddPBMC aliquots were used. In an ICA we distinguish three periods: an infection of PBMC (4 h) following drug incubation period of iddPBMC and EC separately for 20 h; a period of contact (4 h) where iddPBMC are layered onto the EC monolayer and a post-contact period of 48 h, which began after washing off previously added PBMC combined with a media exchange. Media always contained 5% of previously collected (stored frozen) serum of a horse with a known EHV-1 serum neutralising antibody titre of 1:2048, except during the 4 h PBMC infection period and the precontact incubation period (20 h) of EC. Successful infection of EC following the contact period will result in viral replication, cell-to-cell spread into neighbouring cells and EC lysis, which becomes detectable as a 'plaque' resulting in an enumerable 'plaque count per well'. This is the outcome of the assay. Modifications of a previously reported ICA were as follows [8] : freshly isolated, in vitro EHV-1 infected PBMC or EC were incubated with Tx or Ntx for 20 h prior to contact. After ) in a total volume of 250 lL medium added to the EC monolayer (contact period). Plates were then placed on a laboratory rocker inside an incubator (37°C, 5% CO 2 ). After 4 h of gentle circular rocking, the medium was exchanged, PBMC were washed off with MEM until remaining PBMC counts were reduced to <50 cells/well as visually assessed. Fresh media containing EHV-1 specific virus-neutralising antibodies, as well as Tx or NTx were added and plates incubated for another 48 h (post-contact period). Finally, monolayers were fixed and stained with crystal violet solution to visualise plaques, which were counted manually using 49 magnification and reported as plaque counts/ well.
In Experiment 1, expanded immortalised equine carotid artery endothelial cells (iEC) at passage 4 were used in monolayers. They are easy to grow compared with BEC and were used here as proof of concept to examine whether there is an effect of Tx in reducing plaque counts in the monolayer. A total of eight PBMC donors were used (two donors on a given experimental day) and five drugs each tested at 19 and 109 concentration evaluated: ASP, LIDO, FIRO, FLX and DEX and NTx served as a control. Infectious centre assays on a given day were run in duplicate and results (plaque count per well) were averaged. The same experimental set-up was repeated within 14 days.
In Experiments 2 and 3 we used cryopreserved primary CNS-derived (brain) EC (BEC) from eight horse donors. The BEC monolayers from any donor (n = 8) were paired with iddPBMC aliquots of individual animals of a group of six PBMC donor horses resulting in 48 possible pairs. As we wanted to test drugs with different working mechanisms (Lidocaine vs. NSAID vs. corticosteroid) and as we noticed a solid reducing effect during Experiment 1 of any of the selected NSAID (ASP, FIRO, FLX), we selected the cyclooxygenase (COX) type 2 specific drug FIRO for further experiments. Experiments were conducted with the three components LIDO, FIRO and DEX. Infectious centre assays to be run on a given day utilised BEC monolayers of either one of two horse EC donors (aliquots of stored frozen origin) paired with freshly isolated PBMC of one of 2 donors. Infectious centre assays on a given day were run in duplicate and plaque count results averaged. Infectious centre assays of same combinations were repeated within 14 days. Plaque count results of less than 10 plaques per ICA in the untreated monolayer were omitted.
The goal of Experiment 2 was to: 1) Evaluate any Tx effect on BEC and 2) compare the effect of Tx during the pre-and contact period, referred to as '24 h of treatment' or '24-Tx', with Tx during the entire incubation period including the 48 h post-contact period, referred to as '72 h of treatment' or '72-Tx'.
With results of Experiment 2 available we decided for Experiment 3 to only evaluate for effect during the initial 24-Tx period (precontact and contact time). In addition, we selectively treated either PBMC or BEC and compared with the plaque counts of 'both treated' and 'both left untreated'. Identical to Experiments 1 and 2, ICAs on a given day were run in duplicate and results (plaque count per well) averaged. The same experimental set-up was repeated within 14 days. Plaque count results of less than 10 plaques per ICA in the untreated monolayer were omitted.
Data analysis
Analysis of variance (ANOVA) was used for the assays to evaluate the 1) Effect of Tx on cell metabolism of EC or PBMC (AlamarBlue assay); 2) effect of Tx on PBMC or EC infection with EHV-1, or 3) replication of EHV-1 in Tx PBMC or EC (percentage EHV-1 infected PBMC, gB copy numbers per 1 9 10 6 PBMC or EC). As plaque counts were the result of the ICA in Experiments 1-3, the counts of Tx or NTx wells were compared using generalised linear and latent mixed models o . The same was done comparing plaque counts resulting from Tx or NTx virus suspensions in contact with respectively treated or untreated EC monolayers. Differences were considered statistically significant at a P≤0.05.
Results
Pre-experiments: influence of drugs on cell viability or virus replication
First, we tested whether any of the drugs or drug additives had an effect on PBMC or iEC viability, or whether these substances influenced virus replication. Results showed that only some of the highest drug concentrations (between 509 and 1009 of therapeutic plasma concentrations) had an effect on iEC metabolism as evidenced by a >50% reduction of fluorescence in the AlamarBlue assay. Neither the 19 or the 109 drug concentrations significantly altered iEC metabolism (Supplementary Item 1) . Peripheral blood mononuclear cell metabolism remained unchanged despite 1009 of therapeutic plasma concentrations of all five drugs. None of the drug additives at the concentration that would be added at a 19 therapeutic concentration of the actual drugs had an effect on PBMC or iEC metabolism (data not shown). We did not test the additives at higher concentrations. In vitro PBMC infection with EHV-1 was donor-dependent and between 2 and 4% of PBMC became infected (3% AE 0.5). The percentage of EHV-1 infected PBMC (based on flow cytometry results) or viral load in total PBMC (based on quantitative PCR results), did not change with drug or drug additive treatment (Supplementary Items 2 and 3). Adding the virus suspension at two different titres onto LIDO, FIRO or DEX-treated BEC did not result in differences in plaque counts when results were compared with untreated controls. Plaque count results of the 1 9 10 2 PFU/mL of (low titre) virus suspension on BEC monolayers are shown in Figure 1 . Plaques per well at the higher (1 9 10 3 PFU/ mL) titre were too numerous to count.
Experiment 1: Anti-inflammatory drug treatment decreases EHV-1 infection in iEC
Anti-inflammatory drug treatment decreased plaque counts in iEC monolayers in this in vitro contact model of infection. Plaque count results for each drug tested are presented as box-and-whisker plots in Figure 2 . Each of the five drugs when applied to the wells containing iEC monolayers in contact with in vitro infected PBMC showed a significant decrease in plaque count at the 19 (P<0.001) and at the 109 drug concentration (P<0.001) when compared with nontreated monolayers. There was no further decrease in plaque counts when a 109 drug concentration was used in the assays in comparison to the 19 concentration (P = 0.2). There were no significant differences in plaque counts between the drugs used. 2 PFU/mL), followed by further incubation with (same) drug or NTx as before. Results: there is no significant difference in plaque counts between drug-treated and NTx BEC (P = 0.38). Box plots are shown with 0-100% percentile, 50% of data points within the box, the median value as horizontal line in the box and '+' representing the mean plaque count result.
Experiment 2: Anti-inflammatory drug treatment decreases EHV-1 infection in BEC
In subsequent experiments, primary BEC were used as a monolayer. Similar to what was observed with iEC in Experiment 1, a significant plaque count reduction was detected for the selected drugs LIDO, FIRO, DEX (P<0.001) when applied during pre-, contact and post-contact time (i.e. 72-Tx) and compared with the results of untreated wells (Fig 3) . In this experiment, we also evaluated whether treatment of PBMC and BEC prior, during and during post-contact period (72-Tx) was superior to limiting treatment to 'prior' and 'during' contact (24-Tx). There was no significant difference in plaque counts when Tx was discontinued after 24 h compared with a complete 72 h Tx period with any of the 3 drugs (P = 0.2) (Fig 3) .
Experiment 3: Restricted treatment of PBMC, BEC or both with anti-inflammatory drugs and effect on plaque count reduction
In the next series of experiments we tested whether a plaque count reduction could be seen when either PBMC alone, BEC alone or both were incubated with any one of the three drugs LIDO, FIRO, DEX. As we concluded from Experiment 2 that there was no additional decrease in plaque count after a 24 h incubation (Fig 3) , we only applied Tx for the first 24 h (precontact and contact). The incubation with LIDO or FIRO showed significant plaque count reduction only when PBMC and BEC were both incubated prior and during contact (i.e. 24 h) (P<0.001). When only one cell component (PBMC or EC) was incubated, reduction of plaque counts varied (Fig 4a, b) . The only exception was treatment with DEX, where a significant reduction of plaque counts was noted with treatment of PBMC only (Fig 4c) .
Discussion
The basis of this study was a previously described in vitro observation that contact between EHV-1-infected PBMC and a monolayer of EC is necessary for a successful transfer of EHV-1 into EC in the presence of EHV-1 neutralising antibodies [8] . Furthermore, the detection of D-dimers exclusively during EHV-1 viraemia in horses indicates activation of the coagulation cascade, which very likely becomes activated by circulating inflammatory mediators [22] . There is further evidence that proinflammatory cytokines are produced and circulating during EHV-1 viraemia [23] . This observation supported the idea of simultaneous activation of the endothelium during EHV-1 viraemia, resulting in the upregulation of CAM on leucocytes and/or EC. We postulated then that in vivo contact between virus-carrying PBMC and EC is necessary for vascular infection with EHV-1 and contacts are facilitated by the inflammation-induced expression of CAM on both, PBMC and EC. Two independent, recent publications also suggest that it is indeed the infection of PBMC with EHV-1 that increases the likelihood of interaction with EC in in vitro models using EC of non-CNS origin [24, 25] . However, secondary EHV-1 pathology is restricted to highly specialised vasculature including the CNS vasculature, it is further proposed that CAM upregulation and This could make the CNS vasculature increasingly susceptible to interaction with EHV-1 infected PBMC and to subsequent viral infection with longer periods of viraemia and higher magnitude of viraemia, both postulated risk factors for EHM [26] . It does not explain the restricted location of EHV-1 secondary pathology as CAM upregulation is a ubiquitous response of vasculature [23, 27] . One could speculate whether a particular constellation of CAM is necessary for the highly specific locations of EC infection. Cell adhesion molecules in mammalian species include P-selectin, L-selectin, ICAM-1, VCAM, PECAM and LFA-1; ICAM-1 in particular has already been shown to play a role in EC infection with EHV-1 during studies on EHV-1 abortion pathogenesis in the horse [28] .
While it is difficult to study equine CAM expression due to the lack of reagents, it is well known that anti-inflammatory drugs downregulate CAM expression, limiting adhesion and leucocyte trafficking through vascular walls [13, 27] . Here, we tested the hypothesis that anti-inflammatory drugs decrease EC viral infection resulting from in vitro interaction between EHV-1 infected PBMC and EC. We selected three different classes of drugs for treating systemic inflammation in the horse. Nonsteroidal anti-inflammatory drugs (NSAID) are best studied for their cyclo-oxygenase (COX) inhibition resulting in a decreased prostaglandin production. However, NSAID also regulate other cellular pathways activated during inflammation [29] . In the horse, COX exists at least in the form of two isoenzymes, the constitutively expressed COX-1 and as a COX-2 isoform, the latter typically induced by inflammatory mediators. In the first experiment we included two nonselective COX-inhibitors (ASP, FLX) and a COX-2 selective inhibitor (FIRO). Dexamethasone (DEX) is a synthetic corticosteroid and one of its mechanisms of action is the induction of a silencing molecule, Ijb, which binds to nuclear factor kappa b (NF-jb) as a regulator of many cell activating pathways [30] . Least is known about the anti-inflammatory properties of lidocaine (LIDO), a Na + channel blocker and class I antiarrhythmic drug with local anaesthetic properties. Currently, LIDO is widely used as a treatment in equine post-operative colic care and during toxaemia and cytokinaemia. It is administered as a continuous rate i.v. infusion which has shown to decrease neutrophilic extravasation and submucosal inflammation in experimental equine ischaemia models [31] .
In this study we found that all drugs showed a statistically significant reduction in EC infection when using immortalised carotid artery EC. In addition, LIDO, FIRO and DEX showed a similar result in brain-derived EC monolayers. Any post-contact EC treatment seemed unnecessary for a further plaque count reduction, while limiting the contact between infected PBMC and EC appears to be essential to prevent EC-infection. We further showed that statistically significant reduction in EC infection was achieved when both PBMC and EC monolayers were LIDO-or FIRO-treated, with plausible explanation that CAM are typically expressed on the leucocyte and EC surface. This reduction in infection was not caused by any of the drug additives, nor was there a drug effect on direct viral entry. In Experiment 1 using iEC and in Experiment 2 using BEC, we noticed that DEX treatment of cells showed the highest variability in plaque reduction when compared with the other drug classes. In Experiment 3, on the other hand, DEX was the only treatment that resulted in significant plaque count reduction when only PBMC were treated. As PBMC were of different donors in Experiments 1-3 and BEC were also of different donors in Experiments 2 and 3 an explanation for the higher variability could be donor-dependent differences in CNS-(B)EC response to DEX treatments. However, more studies are necessary to verify this response.
We observed, on average, differences in the mean plaque counts in iEC used in Experiment 1 (49 AE 5.4) and BEC used in Experiments 2 and 3 with counts of 37 AE 7.2 and 42 AE 16, respectively. Mean plaque counts of iEC (experiment 1) and BEC (experiment 2) were statistically different (P = 0.001). As all EC monolayers in each experiment were unstimulated and the lowest CAM expression can be expected in barrier-associated vasculature under physiological (resting) conditions, the slightly lower counts in BEC could result from fewer contact interaction when compared with iEC due to lower CAM expression. However, differences between individual BEC donors could be responsible for these observations or differences in culture conditions caused by batch differences of certain media. As there are no known equine specific antibodies against CAM available, transcriptome and next generation sequencing, silencing RNA, or microarray analysis is necessary to demonstrate dynamics and differences between various vascular beds in the horse.
This study was primarily done to explore anti-inflammatory drug intervention of EC infection with EHV-1 under in vitro conditions. However, corticosteroids and NSAID in particular are regularly used by clinicians during EHV-1 outbreaks, specifically in horses which develop acute EHM. Few clinicians use NSAID during early phases of the infection; if so, then to address fever and to improve demeanour and appetite in the febrile horse. While this in vitro study focuses on pathophysiological aspects of EHV-1 infection, in particular to gain insights into the aspects that lead to CNSvasculature break-down following the period of EHV-1 viraemia, our results might suggest and stimulate an earlier and more stringent use of antiinflammatory drugs during early EHV-1 infection with the aim to decrease EC infection at the CNS-barrier vasculature. Prevention of EC infection is one possible area to prevent EHM. Vaccination, inducing high numbers of specific cytotoxic T lymphocytes to limit the extent of viraemia, is an active area of research [32] . Groups have evaluated the use of virustatics during this phase with the aim to shorten the number of viraemic days and to decrease the magnitude of viraemia; however, with equivocal results [33] .
Others have shown activation of monocytes and platelets leading to a procoagulant state during EHV-1 infection [34] . Interestingly, platelets are also blocked by NSAID and in particular by ASP, which is a second argument for a more stringent use of NSAID during EHV-1 infection and viraemia. With results of Experiment 1 available to us, we decided to continue with just one member of the NSAID family, the COX-2 selective drug firocoxib and to compare results to dexamethasone and lidocaine. While this selection was mainly done to limit expenses of elaborate CNS-EC culture systems, firocoxib was also chosen for a more stringent and daily use of an NSAID during febrile periods of early EHV-1 infection. Typically, this period lasts for several days and a drug given at recommended (label) dosing for this period should pose a low risk of causing deleterious sideeffects of gastrointestinal ulceration which are assumed more common with the administration of NSAID, especially with nonselective COX inhibitors. Without further in vivo testing, we do not recommend the use of lidocaine or dexamethasone prior to the onset of EHM.
In conclusion, we have previously demonstrated in vitro evidence that CNS vasculature infection with EHV-1 is caused by contact between the virus infected PBMC and the EC. The contact can be reduced by simultaneous incubation with anti-inflammatories leading to reduced EC infection. Proinflammatory mediator-induced upregulation of adhesion molecules on cell surfaces are a proposed mechanism that is likely involved in the pathogenesis of EC infection and EHM. Thus adhesion molecule dynamics during EHV-1 infection should be investigated in the future and further studies are necessary to refine existing in vitro assay systems.
